Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities


Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery abnormalities that could lead to complications later in life, including heart attack. Although investigators can identify children with KD that have these coronary artery abnormalities, there is no approved additional treatment to decrease coronary artery inflammation and arrest or prevent damage to the coronary arteries. Inflammation and damage to the arterial wall is central to these coronary artery abnormalities. Statins, a class of drugs that is known for lowering cholesterol, have also been shown to decrease inflammation in general as well as at the level of the vessel wall. Therefore, the investigators propose to study the safety of the drug atorvastatin in children with coronary artery abnormalities from KD.

Full Title of Study: “Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2018


  • Drug: Atorvastatin
    • Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)

Arms, Groups and Cohorts

  • Experimental: Atorvasatin
    • Atorvastatin dose titration to maximum tolerated dose

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With SAE
    • Time Frame: At 6 weeks after initiation of study drug
    • Number of participants who experienced an SAE within the 6 week study period

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 2 years to 17 years old

2. Meets clinical criteria for KD according to American Heart Association guidelines (Table 2): Fever (T≥38oC or 100.4oC) ≥ 3 days and ≥ 2 clinical criteria with left anterior descending coronary artery/right coronary artery z-score ≥ 2.5 or an aneurysm (≥ 1.5 x the adjacent segment) of one of the coronary arteries

3. Patient presents within the first 20 days after fever onset

4. Parent or legal guardian able and willing to provide informed consent and subject willing and able to provide assent when appropriate.

5. Post-menarchal females: Negative pregnancy test at screening and willing to use two forms of contraception during the study

6. Males engaging in sexual activity that could lead to pregnancy must use a condom.

Exclusion Criteria

1. Use of a statin, fibrate, or niacin within the 3 months prior to enrollment

2. Have any chronic disease, except asthma, atopic dermatitis, autism or controlled seizure disorder

3. Screening creatine phosphokinase (CK) ≥ 3x upper limit of normal for age

4. Patient taking a CYP3A4 inhibitor (ie. cyclosporine or clarithromycin) in the last 7 days

5. Patient has a history of allergy to atorvastatin or its derivatives

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of California, San Diego
  • Collaborator
    • Children’s Hospital Colorado
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jane C. Burns MD, Chief, Division of Allergy, Immunology, Rheumatology – University of California, San Diego
  • Overall Official(s)
    • Jane C Burns, MD, Principal Investigator, University of California, San Diego

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.